Opdivo vs. Keytruda This month there was disappointment for Bristol-Myers Squibb which has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new ...

Bristol-Myers Squibb must make the case for its Opdivo cancer immunotherapy to be included on England’s Cancer Drugs Fund in lung cancer, after NICE asked for more information on its ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.

Bristol Myers Squibb (BMS) has announced that an injectable version of its cancer immunotherapy Opdivo (nivolumab) has been ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for adults ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...

Opdivo (nivolumab) and Keytruda (pembrolizumab) are brand-name biologic drugs prescribed for several types of cancer. They are given by a healthcare professional as an intravenous (IV) infusion.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay ...